Language selection

Search

Patent 2261994 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 2261994
(54) English Title: FROZEN FOOD PRODUCT CONTAINING HEAT STABLE ANTIFREEZE PROTEIN
(54) French Title: PRODUIT ALIMENTAIRE SURGELE CONTENANT UNE PROTEINE ANTIGEL STABLE A LA CHALEUR
Status: Expired and beyond the Period of Reversal
Bibliographic Data
(51) International Patent Classification (IPC):
  • C07K 14/415 (2006.01)
  • A23G 9/00 (2006.01)
  • A23G 9/32 (2006.01)
  • A23G 9/52 (2006.01)
  • A23J 1/00 (2006.01)
  • C07K 1/14 (2006.01)
  • C12N 15/29 (2006.01)
(72) Inventors :
  • LILLFORD, PETER JOHN (United Kingdom)
  • MCARTHUR, ANDREW JOHN (United Kingdom)
  • SIDEBOTTOM, CHRISTOPHER MICHAEL (United Kingdom)
  • WILDING, PETER (United Kingdom)
(73) Owners :
  • UNILEVER PLC
(71) Applicants :
  • UNILEVER PLC (United Kingdom)
(74) Agent: SMART & BIGGAR LP
(74) Associate agent:
(45) Issued: 2009-02-03
(86) PCT Filing Date: 1997-07-04
(87) Open to Public Inspection: 1998-02-05
Examination requested: 2002-05-01
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): Yes
(86) PCT Filing Number: PCT/EP1997/003634
(87) International Publication Number: WO 1998004699
(85) National Entry: 1999-01-20

(30) Application Priority Data:
Application No. Country/Territory Date
96305497.8 (European Patent Office (EPO)) 1996-07-26

Abstracts

English Abstract


A process for the recovery of AFPs from natural sources, said process
involving the steps of a) isolating an AFP containing juice
from the natural source; b) heat treating the natural source or the AFP
containing juice to a temperature of at least 60 °C; c) removing the
insoluble fraction.


French Abstract

Procédé permettant de récupérer des protéines antigel (AFP) depuis des sources naturelles et consistant à (a) isoler un jus contenant AFP depuis la source naturelle; (b) effectuer le traitement thermique de la source naturelle ou du jus contenant AFP jusqu'à une température d'au moins 60 DEG C; (c) retirer la fraction insoluble.

Claims

Note: Claims are shown in the official language in which they were submitted.


31
WE CLAIM:
1. An antifreeze protein (AFP) having a molecular weight of 25 kDa, 35 kDa or
65-
75 kDa, and having an N-terminal sequence having at least 80% overlap in amino
acids with:
25 kDa AFP:
ALA-THR-ILE-THR-ALA-VAL-ALA-VAL-LEU-LYS-X-THR-VAL-GLU-VAL-X-ILE-VAL-
PRO-THR;
35 kDa AFP:
ALA-GLN-PHE-THR-ILE-THR-ASN-LYS-CYS-GLN-PHE-THR-VAL-TRP-ALA-ALA-X-
VAL-PRO; or
65-75 kDa AFP:
X-GLU-GLN-PRO-ASN-THR-ILE-X-GLY-THR.
wherein X denotes an unknown which may be any amino acid found in plant
proteins, having a thermal stability as evidenced by no significant reduction
in ice
recrystallisation inhibition properties, as evidenced in that the ice crystal
size of a
composition of heat-treated AFP in water after quick freezing to -40°C
followed
by storage at -6°C for 1 hour is less than 5 µm larger than the ice
crystal size of
the same AFP which is not heat-treated, wherein the heat-treatment consists of
1
hour at 60°C, one hour at 80°C or 10 minutes at 100°C.
2. An antifreeze protein (AFP) according to claim 1, wherein the ice crystal
size of a
composition of the AFP in water after quick freezing to -40°C followed
by storage
at -6°C for 1 hour is 15 µm or less.
3. A process for the recovery of an antifreeze protein (AFP) from natural
sources,
having a thermal stability as evidenced by no significant reduction in ice
recrystallisation inhibition properties, as evidenced in that the ice crystal
size of a
composition of heat-treated AFP in water after quick freezing to -40°C
followed
by storage at -6°C for 1 hour is less than 5 µm larger than the ice
crystal size of
the same AFP which is not heat-treated, wherein the heat-treatment consists of
1
hour at 60°C, one hour at 80°C or 10 minutes at 100°C,
said process involving
the steps of

32
I.a isolating a juice which contains the AFP from the natural source and then
heat treating the juice to a temperature of at least 60°C; or
I.b heat treating the natural source to a temperature of at least 60°C
followed
by isolating a juice which contains the AFP from said natural source;
II. removing the insoluble fraction and retaining the AFP rich liquid
fraction;
whereby step I.a or I.b takes place before step II.
4. Frozen confectionery product comprising from 0.0001 to 0.5 wt% of the AFP
according to claim 1.
5. Pre-mix suitable for use in the production of the frozen confectionery
product
according to claim 4, comprising the AFP of claim 1.
6. Process for the preparation of a frozen confectionery product comprising:
(a) the
preparation of a formulation mix comprising 0.0001 to 0.5 wt% of the
antifreeze
protein (AFP) according to claim 1; (b) followed by freezing the mix under
quiescent conditions.

Description

Note: Descriptions are shown in the official language in which they were submitted.


CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
FROZEN FOOD PRODUCT CONTAINING HEAT STABLE ANTIFREEZE PROTEIN
Technical Field of the Invention
The invention relates to a process for the isolation of
anti-freeze proteins (AFPs) and frozen food product
containing AFPs.
Background to the Invention
Anti-freeze proteins (AFPs) have been suggested for
improving the freezing tolerance of foodstuffs.
For the purpose of the invention, the term AFP has the
meaning as well-known in the art, namely those proteins
which exhibit the activity of inhibit the growth of ice
crystals. See for example US 5,118,792.
WO 90/13571 discloses antifreeze peptides produced
chemically or by recombinant DNA techniques. The AFPs can
suitably be used in food-products. Example 3B shows
modified ice crystal shapes if a water-ice mixture is
frozen into a film in combination with 0.01 wt% of AFP.
WO 92/22581 discloses AFPs from plants which can be used
for controlling ice crystal shape in ice-cream. This
document also describes a process for extracting a
polypeptide composition from extracellular spaces of plants
by infiltrating leaves with an extraction medium without
rupturing the plants.
WO 94/03617 discloses the production of AFPs from yeast and
their possible use in ice-cream. WO 96/11586 describes fish
AFPs produced by microbes.

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
z
Several literature places also mention the isolation and/or
use of plant proteins for cryoprotection. Cryoprotective
proteins have a function in the protection of plant
membranes against frost damage. These proteins, however, do
not possess recrystallisation inhibition properties and
are, therefore, not embraced within the terms AFPs.
Hincha in Journal of Plant Physiology, 1992, 140, 236-240
describes the isolation of cryoprotective proteins from
cabbage.
Volger in Biochimica et Biiophysica Acta, 412 (1975), 335-
349 describes the isolation of cryoprotective leaf proteins
from spinach.
Boothe in Plant Physiol (1995), 108: 759-803 describes the
isolation of proteins from Brassica napus. Again, these
proteins are believed to be cryoprotective proteins rather
than AFPs.
Neven in Plant Molecular Biology 21: 291-305, 1993
describes the DNA characterisation of a spinach
cryoprotective protein.
Salzman in Abstracts and Reviews of the 18th Annual Meeting
of the ASEV/Eastern Section in Am. J. Enol. Vitic., Vol.
44, No. 4, 1993 describes the presence of boiling-stable
polypeptides in buds of Vitis. Although the proteins are
analogous to fish antifreeze peptides, they are
cryoprotective proteins and not AFPs.
Lin in Biochemical and Biophysical Research Communication,
Vol. 183, No. 3, 1992, pages 1103-1108 and in Lin, Plant
Physiology (1992) 99, 519-525 describes the 15 kDa
cryoprotective polypeptide from Arabidopsis Hakaira.
Houde in The Plant Journal (1995) 8(4), 583-593 mentions

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
3
cryoprotective proteins from wheat.
Furthermore -as illustrated in example VIII- extracts of
cabbage, spinach, Brassica napus and Arabidopsis do not
. 5 have recrystallisation inhibition proteins after heating.
Up till now, however the use of AFPs has not been applied
to commercially available food products. One reason for
this are the high costs and complicated process for
obtaining AFPs. Another reason is that the AFPs which until
now have been suggested for use in frozen food products
cannot be incorporated in the standard formulation mix,
because they tend to destabilise during processing
especially during the pasteurisation step. This
destabilisation is believed to be caused by the
denaturation of the AFPs; this is a well-known effect
commonly observed for peptides and proteins.
The present invention aims at providing solutions to these
problems.
Surprisingly it has been found that AFPs can be isolated
from natural sources such as cold-acclimatised plants by
means of a new relatively simple process. This process
leads for the first time to the identification of AFPs
which can conveniently be incorporated in a mix for the
preparation of frozen products before the pasteurisation
thereof.
Accordingly in a first aspect, the invention relates to a
process for the recovery of AFPs from natural sources, said
process involving the steps of
a) isolating a AFP containing juice from the natural
source;
b) heat treating the natural source or the AFP
containing juice to a temperature of at least 60oC;
c) removing the insoluble fraction.

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
4
Step c of the above process will usually take place after
steps a and b. Step a and b can be done in any desired
order, for example step a followed by step b (in that case
the AFP rich juice will be heated) or step b followed by
step a (in that case the natural source will be heated) or
step a and b simultaneously.
Surprisingly we have found that the isolation process of
the invention has a number of advantages.
Firstly by using the process it is no longer necessary to
avoid rupturing of the natural source such as plants such
as required in the processes according to WO 92/22581. This
immediately significantly increases the commercial
applicability of the process, for example as compared to WO
92/22581, because high investment costs for specific
processing are no longer necessary.
Also by using the high temperatures it seems possible to
extract from a large group of peptides present in the
natural sources a new selection of very active AFPs from
the natural material, said AFPs including peptides which
are very active w.r.t. ice-recrystallisation inhibition
properties.
Thirdly, contrary to expectations, the use of high
temperatures does not denature all the proteinaceous
material, but does only seem to denature some of the
proteins, while the remaining AFPs have an increased
temperature stability. This renders it possible to include
the isolated AFPs in compositions which need to be
subjected to higher temperatures e.g. a pasteurisation
step. This is especially surprising, because for example
the AFPs from WO 92/22581 appear not stable under heating
conditions (see example VI).
The process of the invention includes in step b the heating

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
S
of the natural source or the AFP rich juice to a
temperature of more than 600C. Preferably the temperature
is from 60 to 110 OC, most preferably from 80 to 1050C. The
heating step can take place after the isolation of the
protein rich juice (step a) or before the isolation of the
protein rich juice. Any suitable way to heat the juice can
be used, for example conventional or microwave heating,
heating optionally with an added extraction medium,
steaming etc.
If an extraction medium is used, preferably it is used in
small volumes to avoid unnecessary dilution of the AFP
fraction. Any suitable extraction medium can be used,
although the use of water is especially preferred. If
desired, additives may be added to the water prior to using
it as an extraction medium. Most preferred, however water
substantially free of additives is used.
The process of the invention can be applied to any natural
source of heat-stable AFPs. Included in this list are -
plants, fishes, insects and microorganisms. Both natural
occurring species may be used or species which have been
obtained through genetic modification. For example micro-
organisms or plants may be genetically modified to express
AFPs and the AFPs may then be isolated in accordance to the
present invention. AFPs having at least 80%, more preferred
more than 95%, most preferred 100% homology to the AFPs
directly obtained from natural sources can thus be
obtained. For the purpose of the invention proteins
possessing this high level of homology are also embraced
within the term AFPs. Also these transformed microorganism
or plants capable of expressing genes encoding the AFPs are
also embraced within the scope of the invention.
Genetic manipulation techniques may be used to produce the
heat stable AFPs described in the invention. An appropriate
host cell or organism would be transformed by a gene

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
6
construct that encodes the desired heat stable polypeptide.
The nucleotide sequence coding for the heat stable
polypeptide can be inserted into a suitable expression
vector containing the necessary elements for transcription
and translation and in a manner that they will be expressed
under appropriate conditions (eg in proper orientation and
correct reading frame and with appropriate targeting and
expression sequences). The methods required to construct
these expression vectors are well known to those skilled in
the art.
A number of expression systems may be utilised to express
the heat stable polypeptide coding sequence. These include,
but are not limited to, bacteria, yeast insect cell
systems, plant cell culture systems and plants all
transformed with the appropriate expression vectors.
A wide variety of plants and plant cell systems can be
transformed with the nucleic acid constructs of the
polypeptides isolated in the heat stable extract. Preferred
embodiments would include, but are not limited to, maize,
tomato, tobacco, carrots, strawberries, rape seed and sugar
beet.
Preferably the AFP is derived from plants (this means that
either the AFP is directly obtained from the plant as
natural source or AFPs having a high degree of homology to
these AFPs are transgenetically produced in other
organisms). Any plant containing heat stable AFPs can be
used, preferably however are naturally occurring plants (or
their genetic modified versions) which are able to grow
under cold conditions such that they contain AFPs.
Especially preferred is the use of winter-rye, perennial
grasses and sedges. Other suitable plants may for example
come from the group of woody plants, winter-cereals etc.
Especially preferably the heat stable AFPs are derived from

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
~
Acer saccharoides, Bamboo, Buddleia, Isothecium
myosuroides, Ramalina farinaceae, Usnea subfloridana,
Forsythia, Oxalis, Poa Trivialis, Lolium Perenne, Holcus
Lanatus, Bromus Sterilis, Parodiochloa flabellata,
Deschampsia antartica, Carex aquatilis, Colobanthus
quintensis and Agrostis tenuis, Festuca contracta and Poa
annua.
The AFP rich juice can be separated from its source by any
convenient process for example pressing, filtering,
homogenising, extraction etc. Preferably the natural source
of AFP such as the plant material is made into small pieces
or into a slurry before the protein rich fraction is
collected, for example by filtering. This maceration can be
done by any suitable method, for example in a blender. It
will be well within the ability of the skilled person to
divide the material into such a form that collection of the
protein rich juice can readily take place.
After collecting and heating (in the desired order) the
protein fraction the resulting AFP containing sample can
then be treated by any convenient process in order to
remove the insoluble traction and retain the AFP rich
liquid fraction. The insoluble fraction can be removed e.g.
by filtering, precipitation etc. The AFP rich liquid can
then advantageously be further processed to concentrate or
isolate the AFPs to bring them in a form suitable for
further use. Examples of suitable processes are drying to
obtain a powder or paste, further concentration to obtain
an AFP concentrate, chromatography to separate the AFPs
from the extraction medium etc. Again it will be well
within the ability of the skilled person to determine the
suitable means and conditions for appropriate isolation.
For some natural sources the AFPs obtained by the above
methods may consist of a mixture of two or more different
AFPs. If desired these AFPs can be separated by any

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
$
conventional process for example chromatography or other
processes based on the differences in physical/chemical
properties such as molecular weight.
Also if desired the amino acid composition and sequence of
the isolated AFPs can be determined. Any suitable method
for determining these can be used. Examples of suitable
methods are described in the examples. Also if desired the
nucleic acid sequence that encodes the AFPs can be
determined. Vector containing a nucleic acid sequence
capable of encoding the amino acids are also embraced
within the scope of the invention.
Based on the above information it is also possible to
genetically modify other natural sources such that
they produce the advantageous AFPs as identified here-
above. Examples of suitable AFPs are described in the
examples.
It has been found that the AFPs obtained by the above
process have an increased ability to withstand thermal
treatment. It is believed that such AFPs have never before
been isolated. As described above this increased thermal
resistance is particularly of interest for use in food-
products which undergo a heating step, for example
pasteurisation.
Accordingly another aspect of the invention relates to AFPs
which have a thermal stability as evidenced by no
significant reduction in the recrystallisation inhibition
properties after heat-treatment for one hour at 800C or 10
minutes at 1000C. A suitable test for determining the ice
recrystallisation inhibition properties is described in the
examples and involves the quick freezing to -400C followed
by storage for one hour at -60C. Preferably AFPs which are
subject to this test after heat-treatment result in an ice
crystal particle size which is less than 5 -pn larger than

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
9
the ice crystal size of a sample with the same AFP which
was not heat-treated. Preferably the difference is less
than 3 um, most preferred less than 1}im.
Preferably those AFPs are chosen which have significant
ice-recrystallisation inhibition properties. A suitable
test for determining the recrystallisation inhibition
properties is indicated in the example VI. Preferably AFPs
in accordance to the invention provide a ice particle size
following an ice recrystallisation inhibition assay -as
described in the examples- of 15 pM or less, more preferred
from 5 to 15 pm.
The AFPs can conveniently be used in food products,
preferably in food products which are frozen or intended to
be frozen. Especially preferred is the use of AFPs in
products which are heated e.g. by pasteurisation or
sterilisation prior to freezing. Especially preferred is
the use in frozen confectionery products.
Examples of such food products are: frozen confectionery
mixes such as ice-cream mixes and water-ice mixes which are
intended to be pasteurised prior to freezing. Such mixes
are usually stored at ambient temperature. Suitable product
forms are for example: a powder mix which is packed for
example in a bag or in sachets. Said mix being capable of
forming the basis of the frozen food product e.g. after
addition of water and optionally other ingredients and -
optional- aeration.
Another example of a suitable mix could be a liquid mix
(optionally aerated) which, if necessary after addition of
further components and optional further aeration can be
frozen.
The clear advantage of the above mentioned mixes is that
the presence of the AFP ingredient makes that the mixes can

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
.i o
be frozen under quiescent conditions, for example in a shop
or home freezer without the formation of unacceptable ice
crystal shapes and hence with a texture different to
products normally obtained via quiescent freezing.
Very conveniently these mixes are packed in closed
containers (e.g. cartons, bags, boxes, plastic containers
etc). For single portions the pack size will generally be
from 10 to 1000 g. For multiple portions pack sizes of up
to 500 kg may be suitable. Generally the pack size will be
from 10 g to 5000 g.
As indicated above the preferred products wherein the AFPs
are used are frozen confectionery product such as ice-cream
or water-ice. Preferably the level of AFPs is from 0.0001
to 0.5 wt% based on the final product. If dry-mixes or
concentrates are used, the concentration may be higher in
order to ensure that the level in the final frozen product
is within the above ranges.
Surprisingly it has been found that compositions of the
invention can contain very low amounts of AFPs while still
being of good quality.
Surprisingly it has been found that the level of AFPs can
be as low as 0.1 to 50 ppm while still providing adequate
recrystallisation properties and temperature tolerance in
frozen confectionery products. Although applicants do by no
means wish to be bound by any theory, the reason for this
may be that the interaction between the solids of the
frozen confectionery and the AFPs provides an excellent
mechanism for inhibiting crystal growth. Most conveniently
the level of AFP is from 1 to 40 ppm, especially preferred
from 2 to 10 ppm.
For the purpose of the invention the term frozen
confectionery product includes milk containing frozen

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
1~)
confections such as ice-cream, frozen yoghurt, sherbet,
sorbet, ice milk and frozen custard, water-ices, granitas
and frozen fruit purees. For some applications the use in
fermented food products is less preferred.
Preferably a the level of solids in the frozen confection
(e.g. sugar, fat, flavouring etc) is more than 4 wt%, for
example more than 30 wt%, more preferred from 40 to 70wto.
Frozen confectionery products according to the invention
can be produced by any method suitable for the production
of frozen confectionery. Especially preferably however all
the ingredients of the formulation are fully mixed before
pasteurisation and before the freezing process starts. The
freezing process may advantageously involve a hardening
step, for example to a temperature of -30 Fahrenheit or
lower.

CA 02261994 2005-11-15
WO 98/04699 PCT/EP97/03634
42
Example I
Isolation of AFPs by first collecting the juice followed by
heat treatment and isolation of the AFP.
Winter rye (Halo variety) was cut in January (mean
temperature in that month was 3.5 oC ensuring the
appropriate cold acclimatization of the plants). The
tissue was rapidly transported into the laboratory for
further handling and washed thoroughly with water to remove
dirt.
400 g of the clippings were homogenised at ambient
temperature in a Waring*blender with 800 g water until the
leaf tissue was completely disrupted. The AFP rich juice
was collected by filtering through 4 layers of muslin.
The AFP rich juice was then subjected to a temperature
treatment by boiling the juice for 10 minutes. This caused
the precipitation of protein while the AFP for use in
accordance to the invention remained in solution. The
supernatant was separated from the precipitate by
centrifuging at 15,000 g for 20 minutes or by further
filtration through muslin.
The AFPs can be isolated from the supernatant by freeze
drying.
For control purposes an _apoplast-ic -ex-tract (extracellular
extract) of winter rye can be obtained as follows: The
leaves from 30 days cold acclimated rye plants were cut
into 3 cm lengths and thoroughly washed in distilled water
to remove any cell contents. The leaf pieces were patted
dry on paper towel and totally immersed in an extraction
medium of 5 mM EDTA, 10 mM ascorbic acid, 2 mM caproic
acid, 2 mM benzamidine and 1 mM Phenylmethylsulphonyl
Fluoride (PMSF). They were then vacuum infiltrated in a
* trade-mark

CA 02261994 2005-11-15
WO 98/04699 PCT/EP97/03634
Buchner flask for 60 minutes after which time the leaves
were removed and patted completely dry. They were then
arranged lengthways is a cut off plastic syringe barrel and
centrifuged gently at 2000 X g for 30 minutes. The
apoplastic extract was collected in an eppendorf tube below
the syringe.
* trade-mark

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
44
Example II
Isolation of AFPs by first heating the natural source,
followed by isolating the AFP rich juice and isolation of
the AFP.
Mixed grass tissue (Poa Trivialis, Lolium Perenne, Holcus
Lanatus, Bromus Sterilis) was cut in January (mean
temperature in that month was 3.5 oC ensuring the
appropriate cold acclimatization of the plants). The grass
tissue was rapidly transported into the laboratory for
further handling and washed thoroughly with water to remove
dirt.
500 g of grass clippings was placed in a 650 Watt microwave
oven and heated at full power for 5 minutes, whereby the
temperature was raised to 85 to 1000C. The grass clippings
were then cooled to ambient temperature.
Alternatively the grass clippings are mixed with 500 g
boiling water and the mixture is re-heated to 100 C
followed by boiling for 10 minutes under stirring and then
allowed to cool to 60 C.
After the heating step the AFP rich juice was separated
from the clippings by filtering. The mass was stirred
continuously for 5 minutes in the presence of an equal
volume of water and then squeezed through 3 layers of
muslin.
The supernatant can be freeze dried to remove the water
followed by storage. Alternatively the supernatant can be
frozen for storage.

CA 02261994 2005-11-15
WO 98/04699 PCT/EP97/03634
Example III
A liquid pre-mix for preparing ice-cream was made by
mixing:
5
Ingredient % by weight
Skimmed milk powder 11.390
Sucrose 3.410
Maltodextrine (MD40) 4.000
10 Locust bean gum 0.072
Corn Syrup 63DE 20.705
Guar Gum 0.048
Genulacta L100 0.020
Butter 9.015
15 Avicel* RC581 0.240
Gelatin 0.140
Monoglyceride (palmitate) 0.450
Vanillin 0.010
AFP (of example 1*) 0.100 or none (control)
20 Water balance
*Note: AFP is added as concentrated AFP solution using some
of the added water as a diluent , percentage refers to
amount of AFP.
This mix can conveniently be pasteurised at 850C for 15
seconds and stored chilled in a can.
The mixes can be used in the preparation af 1~:-~ce~c~e~~ 30 whipping with a
conventional house-hold mixer to an overrun
of about 100%, followed by quiescently freezing into a
house-hold freezer. The composition according to the
invention had a markedly better texture than the control
sample.
Very good results are obtained by using the AFP of Example
II instead of the AFP of example I.
* trade-mark

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
'-6
Example IV
A liquid premix for the preparation of ice-cream was
prepared by mixing:
Ingredient % by weight
Skimmed milk powder 10.00
sucrose 13.00
maltodextrine (MD40) 4.00
Locust bean gum 0.14
butter oil 8.00
monoglyceride (palmitate) 0.30
vanillin 0.01
AFP (of example I*) 0.01 or none(control)
water balance
*Note: AFP is added as concentrated AFP solution in some of
the water, percentage refers to amount of AFP.
The ingredients were mixed at ambient temperature followed
by pasteurisation for 60 seconds at 890C. The mix was
aseptically filled into packs of 500 ml, sealed and stored
at ambient temperatures.
The mix can be used for the preparation of ice-cream by
whipping it with a conventional house-hold mixer to an
overrun of about 70 % followed by freezing under quiescent
conditions in a house-hold freezer.
After two months storage the composition according to the
invention had a markedly better texture than the control
sample.
Very good results are obtained by using the AFP of Example
II instead of the AFP of example I.

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
Examnle V
Example IV was repeated, but now the ice-cream mix was pre-
aerated to an overrun of 70 % prior to aseptically filling
and sealing.
The resulting product can be stored at ambient temperature
and an ice-cream can be produced by placing the mix in a
house-hold freezer and freezing under quiescent conditions.

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
4$
Example VI
The ice recrystallisation inhibition properties of the AFPs
can determined as follows:
A sample of an AFP containing product was adjusted to a
sucrose level of 30 wt% (If the starting level of the
sample was more than 30% this was done by dilution, if the
starting level was lower sucrose was added to the 30%
level).
A 3 pL drop of the sample was placed on a 22 mm coverslip.
A 16 mm diameter cover-slip was then placed on top and a
200 g weight was placed on the sample to ensure a uniform
slide thickness. The edges of the coverslip were sealed
with clear nail varnish.
The slide was placed on a Linkham THM 600 temperature
controlled microscope stage. the stage was cooled rapidly
(50 oC per minute) to -400C to produce a large population
of small crystals. The stage temperature was then raised
rapidly (500C per minute) to -6 oC and held at this
temperature.
The ice-phase was observed at -6 oC using a Leica
Aristoplan microscope. Polarised light conditions in
conjunction with a lambda plate were used to enhance the
contrast of the ice crystals. The state of the ice phase
(size of ice crystals) was recorded by 35 mm
photomicrography at T=0 and T=l hour.
Generally this test can be applied to any suitable
composition comprising AFP and water. Generally the level
of AFP in such a test composition is not very critical and
can for example be from 0.0001 to 0.5 wt%, more preferred
0.0005 to 0.1 wt%, most preferred 0.001 to 0.05 wt%, for
example 0.01 wt%

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
Any suitable composition comprising AFP and water can be
used to carry out the test. Generally, however, it will not
be necessary to obtain the AFP in purified form. For
practical applications normally it would suffice to prepare
= 5 a liquid extract or juice of natural material, wherein this
extract or juice can then be tested.
This method can be applied for example to the AFP
containing extracts as obtained in example I or II, with or
without a concentration step.
The recrystallisation inhibition properties of several
samples was measured. The samples were obtained from rye
which were harvested at several moments during the year.
The AFP juices obtained after.extraction and heating in
accordance to example I were measured for their
recrystallisation properties as above. As a comparison rye
was used which was grown in a greenhouse (at temperatures
which normally do not induce AFP formation)
The following ice crystal sizes were measured
Sample Ice crystal size after 1 hour (pun)
Control 25
sample December 17
sample January 10
sample February 15
sample March 18
sample April 18
sample May 25
These measurements show that for good AFP activity the
plants should be harvested during the winter months e.g.
December-April. Especially preferred are samples capable of
providing ice crystal sizes of 15 pm or less. In this case
this can be achieved by harvesting the plants in January or
February.

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
2,0
The same measurements were done on the AFP samples of
January which were heat treated (1 hour at 60 OC). No
significant reduction in recrystallisation properties was
observed.
As a comparison the apoplastic extract of example I was
used. This resulted in a final ice crystal size after 1
hour of 11.1 }im; after heat treatment by boiling for 10
minutes at 100 C the test resulted after 1 hour in a ice
crystal size of 16.8 pm. This example shows that the
apoplastic extract from winter rye is not heat stable.

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
2!
Example VII
Non heat treated grass extract from grass harvested in
January was obtained from Silsoe (UK). The extract was
centrifuged for 1 hour to remove soil and insoluble debris
as follows, Centrifuge:Sorvall RC3C, Rotor
:H6000A,Temperature:+5 C, Rotor Speed:5000rpm(7268g).
A sample of the extract was freeze dried to determine its
total solids content. This was found to be 11.48 mg/ml. The
dried extract was then rehydrated with 30% Sucrose solution
to its original total solids concentration. Several
solutions were prepared by diluting the extract as
necessary with 30% Sucrose solution.
Antifreeze activity was measured using the assay of example
VI.
The T=0 and T=1 hour pictures from the recrystallisation
inhibition assays had their mean ice crystal sizes measured
using the Zeiss TGA 10 analyser. The results obtained are
shown in the table below.
Ice Crystal Size Ice Crystal
Sample Total (um) Growth in 1
Solids T=0 T=1 hour hour at -6 C
(mg/ml) at -6 C (M)
Undiluted 11.48 5.2 7.3 2.1
50% Extract 5.74 5.5 7.6 2.1
25% Extract 2.87 6.3 8.9 2.6
12.5% Extract 1.435 6.6 13.1 6.5
6.25% Extract 0.7175 8.1 14.7 6.6

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
22
3.125% 0.359 7.4 17.0 9.6
Extract
1.5625% 0.179 9.0 20.3 11.3
Extract
These results show the variation in final crystal size and
the change in ice crystal size over 1 hour at -6 C for the
various dilutions of grass extract. It can be seen that the
solids level in the grass extract can be varied in a wide
range while still good recrystallisation inhibition
properties are obtained. Preferably those concentrations
are chosen which result in an ice crystal size after 1 hour
of 15 micrometer or less.
A similar test was done with grass extract which had been
subjected to heat treatment (10 minutes at 100 C). No
significant deterioration of recrystallisation inhibition
properties was seen.
Additionally the grass extracts of example II were tested
using the same recrystallisation inhibition test. The
following results were obtained:
Heat Crystal Size in }im
treatment T=0 T=1
60 C 1 hour 9.6 11.1
Boil 10 minutes 9.8 11.3
These results show that even after heating the extract of
cold acclimatised grass maintained the ability to inhibit
ice crystal growth.

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
Exarnple VIII
Several AFP containing plants were harvested in January.
5 Extracts were obtained by grounding fresh tissue, for
example roots, stems, buds or leaves with a pestle and
mortar (cooled to 4 C) in a equal volume of buffer A (10
mM EDTA, 20 mM Ascorbic acid, buffered with Tris to pH 7.4)
held on ice. The homogenates are filtered through one or
10 more layers of muslin and kept on ice prior to further
used.
The extracts were subjected to the recrystallisation
inhibition test of example VI both after heating for 60 C
15 for 1 hour and boiling for 10 minutes.
The following plants contained heat stable AFPs as
evidenced by the maintenance of recrystallisation
inhibition properties: Acer saccharoides, Bamboo, Buddleia,
Isothecium myosuroides, Ramalina farinaceae, Usnea
subfloridana, Forsythia, Oxalis, Poa Trivialis, Lolium
Perenne, Holcus Lanatus, Bromus Sterilis, Parodiochloa
flabellata, Deschampsia antartica, Carex aquatilis,
Colobanthus quintensis and Agrostis tenuis, Festuca
contracta and Poa annua.
The following plants did not contain heat stable AFPs:
cabbage, spinach, Brassica napus and Arabinopsis.

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
z4
Example IX
The thermal hysteresis activity of the AFPs can be tested
as follows:
1 ml samples were placed in Eppendorfs in a hot water bath
and heated for 1 hour at 60 OC. The thermal hysteresis
properties of the sample were then measured as follows:
The melted product is placed on a microslide (Camlab
Cambridge, path length 0.1 mm). The ends of the microslide
are sealed with petroleum jelly.
Ice is introduced into the sample using an aerosol freezing
spray. The slide was then immersed in ethanol temperature
regulated bath at -0.1 OC. After 5 minute equilibration the
sample is checked. if the ice melts completely the
temperature of the bath was lowered in 0.10C steps followed
by equilibration. These steps are repeated until a
temperature was reached where a small amount of ice
crystals exist in the sample. After equilibration at that
temperature, the bath temperature was decreased in steps of
0.01 oC per minute. The freezing point of the sample is
recorded as the temperature at which the ice propagation
begins from the equilibrated crystals.
The melting temperature of the sample is then determined by
raising the temperature starting at the freezing point in
steps of 0.01 OC per minute until all ice crystals melt.
This temperature is the melting temperature of the sample.
The thermal hysteresis of the sample is the difference
between the melting temperature and the freezing
temperature.
This test procedure is done on a first sample (prior to

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
heat treatment) and on a second sample after heat
treatment, followed by cooling.
Similarly the heat stability can be determined by the above
5 test wherein the sample is boiled in water for 30 seconds
followed by determining the thermal hysteresis.
The thermal hysteresis of several samples was measured.
The samples were obtained from winter-rye which were
10 harvested at several moments during the year. The AFP
juices obtained after extraction and heating in accordance
to example I were measured for their thermal hysteresis as
in example VI. As a comparison winter-rye was used which
was grown in a greenhouse (at temperatures which normally
15 do not induce AFP formation)
The following thermal hysteresis was measured
Sample Thermal hysteresis ( oC)
Control 0.04
sample December 0.18
sample January 0.21
sample February 0.17
sample March 0.15
sample April 0.12
sample May 0.05
These measurements show that for good AFP activity the
plants should be harvested during the winter months e.g.
December-March.
The same measurements were done on the AFP samples of
January which were heat treated (1 hour at 600C) No
significant reduction in thermal hysteresis was observed.

CA 02261994 2005-11-15
WO 98/04699 PCT/EP97/03634
26
Example X
Determination of amino acid sequence of AFPs
The heat stable grass extract of example II was
concentrated approximately ten times using an Amicori
ultrafiltration chamber with lOkDa cut-off membrane. The
resulting concentrate was loaded onto a Mono Q*(Pharmacia)
HR 5/5 FPLC anion exchange column. Binding to the column
was in 50mM Tris/HC1 buffer pH 8.5 and the RI active
fraction was eluted with a linear gradient of NaCl to a
final concentration of 0.5M in the same pH 8.5 Tris buffer.
Chromatography was carried out at a flow rate of lml miri'
and 1 ml fractions were collected and assayed for
recrystallisation inhibition activity (as in example IX).
The active fractions were pooled together and concentrated
to a volume of 0.05 ml on a centricon PM10 centrifugal
concentrator (Amicon) centrifuged at 10,000rpm for 10
minutes in a Sorvall SS 34 rotor (8 x 50 ml). The
concentrate was loaded onto a Superdex 75 PC 3.2/30 gel
filtration column running on a SMART microseparation system
(Pharmacia). The column was eluted with 50mM Tris/HC1
buffer pH 8.5 at a flow rate of 0.05 ml miri'. Fractions of ~-~
0.05 ml were collected after the sample was loaded to a
total volume of 3.5 ml. Fractions were assayed for
recrystallisation inhibition activity (as in example IX)
and the mos+ actiw fractions were subjected to separation
on an SDS PAGE gel and electroblotting prior to N-terminal
sequencing.
The active Superdex*75 fractions were taken up in gel
loading buffer (50mM Tris/HC1, pH 6.8, 10% glycerol, 10mM
dithiothreitol, 2% SDS) and then separated on a 10%
polyacrylamide gel following the Laemmli method. After
electrophoresis the gel was sandwiched against a sheet of
* trade-mark

CA 02261994 2005-11-15
WO 98/04699 PCT/EP97103634
methanol wetted Problott* (Perkin Elmer) membrane and
electroblotted at 20 volts for 16 hours in 10mM 3(cyclo-
hexylamino) - 1 - propane sulphonic acid (CAPS) buffer (pH
11.0) containing 10% methanol. After blotting, the membrane
was washed briefly with methanol and then milli Q*
(Millipore) water and the bound proteins visualised with a
solution of 0.1 0(w/v) coomassie*brilliant blue.
Two protein bands of apparent molecular weights 25kDa and
35kDa were visualised by the coomassie staining. The 35 kDa
protein appeared to particularly closely correlate to the
most RI active fractions. Both of these bands were excised
with a scalpel blade and sequenced. An unstained area of
the membrane corresponding to an apparent molecular weight
of 65 - 75 kDa was also subjected to sequencing as silver
staining of gels of the most active fractions had
previously shown a protein band at this molecular weight.
All three excised areas of membrane were sequenced by
loading into a Blott sequencing cartridge and the sequence
determined using reaction and conversion cycles as
described by the manufacturer (Perkin-Elmer). N-terminal
sequence-listings are given below.
The 25 kDa AFP comprises a sequence from the N terminus
substantially homologous to:-
ALA-THR-ILE-THR-ALA-VAL-ALA-VAL-LEU-LYS-X-THR-VAL-GLU-VAL-
X-ILE-VAL-PRO-THR
The 35 kDa AFP comprises a sequence from the N terminus
substantially homologous to:-
ALA-GLN-PHE-THR-ILE-THR-ASN-LYS-CYS-GLN-PHE-THR-VAL-TRP-
ALA-ALA-X-VAL-PRO
* trade-mark

CA 02261994 1999-01-20
WO 98/04699 PCT/EP97/03634
zs
The 65-70 kDa AFP comprises a sequence from the N terminus
substantially homologous to:-
X-GLU-GLN-PRO-ASN-THR-ILE-X-GLY-THR
In each sequence X denotes an unknown which may be any
amino acid found in plant proteins. For the purpose of the
invention the term substantially homologous refers to at
least 80 a overlap in amino acids, more preferred more than
90t, most preferred 95 to 100%.

CA 02261994 2005-11-15
29
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: UNILEVER PLC
(B) STREET: UNILEVER HOUSE, BLACKFRIARS, LONDON
(C) CITY: LONDON
(E) COUNTRY: ENGLAND
(F) POSTAL CODE (ZIP): EC4P 4BQ
(ii) TITLE OF INVENTION: FROZEN FOOD PRODUCT CONTAINING HEAT STABLE
ANTIFREEZE PROTEIN
(iii) NUMBER OF SEQUENCES: 3
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
(v) CURRENT APPLICATION DATA:
APPLICATION NUMBER: CA 2,261,994
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
Ala Thr Ile Thr Ala Val Ala Val Leu Lys Xaa Thr Val Glu Val Xaa
1 5 10 15
Ile Val Pro Thr
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: protein

CA 02261994 2005-11-15
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
Ala Gln Phe Thr Ile Thr Asn Lys Cys Gln Phe Thr Val Trp Ala Ala
1 5 10 15
Xaa Val Pro
(2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
Xaa Glu Gln Pro Asn Thr Ile Xaa Gly Thr
1 5 10

Representative Drawing

Sorry, the representative drawing for patent document number 2261994 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Time Limit for Reversal Expired 2015-07-06
Letter Sent 2014-07-04
Grant by Issuance 2009-02-03
Inactive: Cover page published 2009-02-02
Inactive: Final fee received 2008-11-17
Pre-grant 2008-11-17
Notice of Allowance is Issued 2008-06-16
Letter Sent 2008-06-16
Notice of Allowance is Issued 2008-06-16
Inactive: IPC removed 2008-06-06
Inactive: First IPC assigned 2008-06-06
Inactive: Approved for allowance (AFA) 2008-05-29
Amendment Received - Voluntary Amendment 2007-08-13
Inactive: S.30(2) Rules - Examiner requisition 2007-06-12
Amendment Received - Voluntary Amendment 2006-10-16
Amendment Received - Voluntary Amendment 2006-09-28
Inactive: S.30(2) Rules - Examiner requisition 2006-06-06
Inactive: Delete abandonment 2006-04-19
Inactive: Adhoc Request Documented 2006-04-19
Inactive: Delete abandonment 2006-04-19
Inactive: IPC from MCD 2006-03-12
Inactive: IPC from MCD 2006-03-12
Inactive: IPC from MCD 2006-03-12
Inactive: IPC from MCD 2006-03-12
Inactive: Abandoned - No reply to s.30(2) Rules requisition 2006-02-03
Inactive: Abandoned - No reply to s.29 Rules requisition 2006-02-03
Amendment Received - Voluntary Amendment 2005-11-15
Inactive: S.30(2) Rules - Examiner requisition 2005-08-03
Inactive: S.29 Rules - Examiner requisition 2005-08-03
Amendment Received - Voluntary Amendment 2003-01-24
Letter Sent 2002-06-19
Request for Examination Received 2002-05-01
Request for Examination Requirements Determined Compliant 2002-05-01
All Requirements for Examination Determined Compliant 2002-05-01
Inactive: Correspondence - Formalities 1999-10-01
Inactive: Office letter 1999-09-14
Inactive: Delete abandonment 1999-08-18
Deemed Abandoned - Failure to Respond to Notice Requiring a Translation 1999-07-26
Inactive: Correspondence - Formalities 1999-07-23
Inactive: First IPC assigned 1999-04-01
Classification Modified 1999-04-01
Inactive: IPC assigned 1999-04-01
Inactive: IPC assigned 1999-04-01
Inactive: IPC assigned 1999-04-01
Inactive: IPC assigned 1999-04-01
Inactive: Incomplete PCT application letter 1999-03-23
Inactive: Notice - National entry - No RFE 1999-03-17
Application Received - PCT 1999-03-15
Application Published (Open to Public Inspection) 1998-02-05

Abandonment History

Abandonment Date Reason Reinstatement Date
1999-07-26

Maintenance Fee

The last payment was received on 2008-06-18

Note : If the full payment has not been received on or before the date indicated, a further fee may be required which may be one of the following

  • the reinstatement fee;
  • the late payment fee; or
  • additional fee to reverse deemed expiry.

Please refer to the CIPO Patent Fees web page to see all current fee amounts.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
UNILEVER PLC
Past Owners on Record
ANDREW JOHN MCARTHUR
CHRISTOPHER MICHAEL SIDEBOTTOM
PETER JOHN LILLFORD
PETER WILDING
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Description 1999-10-01 30 1,043
Description 1999-01-20 28 1,009
Abstract 1999-01-20 1 47
Claims 1999-01-20 3 70
Cover Page 1999-04-21 1 29
Description 2005-11-15 30 1,047
Claims 2005-11-15 2 61
Claims 2006-09-28 2 56
Claims 2006-10-16 2 58
Claims 2007-08-13 2 57
Cover Page 2009-01-16 1 31
Reminder of maintenance fee due 1999-03-16 1 111
Notice of National Entry 1999-03-17 1 193
Courtesy - Certificate of registration (related document(s)) 1999-03-17 1 117
Reminder - Request for Examination 2002-03-05 1 119
Acknowledgement of Request for Examination 2002-06-19 1 193
Commissioner's Notice - Application Found Allowable 2008-06-16 1 165
Maintenance Fee Notice 2014-08-15 1 172
PCT 1999-01-20 13 423
Correspondence 1999-03-23 1 38
Correspondence 1999-07-23 4 97
Correspondence 1999-09-07 1 14
Correspondence 1999-10-01 4 92
Fees 2003-06-18 1 30
Fees 2000-06-08 1 29
Fees 2001-07-03 1 31
Fees 2002-06-19 1 33
Fees 1999-06-21 1 25
Fees 2004-06-18 1 37
Fees 2005-06-20 1 29
Fees 2006-06-20 1 28
Fees 2007-06-19 1 29
Fees 2008-06-18 1 36
Correspondence 2008-11-17 1 33

Biological Sequence Listings

Choose a BSL submission then click the "Download BSL" button to download the file.

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.

Please note that files with extensions .pep and .seq that were created by CIPO as working files might be incomplete and are not to be considered official communication.

BSL Files

To view selected files, please enter reCAPTCHA code :